Lewes, DE -- (SBWIRE) -- 01/22/2019 -- Global Human Rabies Immunoglobulin (IM) market will register a 7.3% CAGR in terms of revenue, reach US$ 440 million by 2023, from US$ 290 million in 2017.

Rabies immunoglobulin (RIG) is a medication made up of antibodies against the rabies virus. It is used to prevent rabies following exposure.

Figure Human Rabies Immunoglobulin (IM) is rabies immunoglobulin antibody by the high price of healthy human plasma protein low temperature ethanol separation or other separation methods approved separation and purification, and by virus removal and inactivation treatment is made. Mainly used for rabies or other crazy animal bites, scratches patient's passive immunization.

In this report, we study ERIG (Equine Rabies Immunoglobulin) and HRIG (Human Rabies Immunoglobulin)
Rabies immunoglobulin (RIG) is a medication made up of antibodies against the rabies virus. It is used to prevent rabies following exposure. It is given after the wound is cleaned with soap and water or providone-iodine and is followed by a course of rabies vaccine.

The use of rabies immunoglobulin in the form of blood serum dates from 1891. Use become common within medicine in the 1950s. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system.

The classification according to the material of Human Rabies Immunoglobulin (IM) includes ERIG, HRIG, and the proportion of HRIG in 2017is about 86.7%, and the proportion is in increasing trend from 2013 to 2017.
Over the next five years, study projects that Human Rabies Immunoglobulin (IM) will register a 7.3% CAGR in terms of revenue, reach US$ 440 million by 2023, from US$ 290 million in 2017.

This report presents a comprehensive overview, market shares, and growth opportunities of Human Rabies Immunoglobulin (IM) market by product type, application, key manufacturers and key regions.

To calculate the market size, study considers value and volume generated from the sales of the following segments:

Segmentation by product type:
ERIG
HRIG
Segmentation by application:
Category II Exposure
Category III Exposure

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report:
CSL Behring
Grifols
Sanofi
Sichuan Yuanda Shuyang
CNBG
Kamada
CBPO
Shuanglin Bio
Weiguang Bio
Shanghai RAAS
Bharat Serum
VINS

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives
To study and analyze the global Human Rabies Immunoglobulin (IM) consumption (value & volume) by key regions/countries, product type and application, history data from 2013 to 2017, and forecast to 2023.
To understand the structure of Human Rabies Immunoglobulin (IM) market by identifying its various subsegments.
Focuses on the key global Human Rabies Immunoglobulin (IM) manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Human Rabies Immunoglobulin (IM) with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Human Rabies Immunoglobulin (IM) submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.

Spanning over 167 pages "Forecast of Global Human Rabies Immunoglobulin (IM) Consumption Market 2023" report covers Scope of the Report, Executive Summary, Global Human Rabies Immunoglobulin (IM) by Players, Human Rabies Immunoglobulin (IM) by Regions, Market Drivers, Challenges and Trends, Marketing, Distributors and Customer, Global Human Rabies Immunoglobulin (IM) Market Forecast, Key Players Analysis, Research Findings and Conclusion.

Please visit this link for more details: https://www.marketresearchreports.com/mrrpb2/forecast-global-human-rabies-immunoglobulin-im-consumption-market-2023

Find all Pharma and Healthcare Reports at: https://www.marketresearchreports.com/pharma-healthcare

For related reports please visit: https://www.marketresearchreports.com/search/site/Human%20Rabies%20Immunoglobulin

Read our Interactive Market Research Blog

About MarketResearchReports.com
MarketResearchReports.com is world's largest store offering quality market research, SWOT analysis, competitive intelligence and industry reports. We help Fortune 500 to Start-Ups with the latest market research reports on global & regional markets which comprise key industries, leading market players, new products and latest industry analysis & trends.

Contact us for your market research requirements: https://www.marketresearchreports.com/contact